You have accessJournal of UrologyTransplantation & Vascular Surgery: Renal Transplantation & Vascular Surgery I1 Apr 2016MP29-14 SERUM N-GLYCAN PROFILING PREDICT ANTIBODY MEDIATED REJECTION IN PATIENTS UNDERGOING LIVING KIDNEY TRANSPLANTATION Daisuke Noro, Tohru Yoneyama, Yuki Tobisawa, Shingo Hatakeyama, Mitsuru Saito, Yasuhiro Hashimoto, Takuya Koie, Shigeru Sato, and Chikara Ohyama Daisuke NoroDaisuke Noro More articles by this author , Tohru YoneyamaTohru Yoneyama More articles by this author , Yuki TobisawaYuki Tobisawa More articles by this author , Shingo HatakeyamaShingo Hatakeyama More articles by this author , Mitsuru SaitoMitsuru Saito More articles by this author , Yasuhiro HashimotoYasuhiro Hashimoto More articles by this author , Takuya KoieTakuya Koie More articles by this author , Shigeru SatoShigeru Sato More articles by this author , and Chikara OhyamaChikara Ohyama More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1098AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Antibody-mediated rejection (ABMR) is a recognized cause of allograft loss in kidney transplant recipients. However, acute ABMR is a diagnostic challenge in living kidney transplantation (LKTx) medicine, because no definitive biomarkers are available. Therefore, early ABMR detection is critical, and there is a need to identify serum markers for improving diagnostic accuracy and predicting graft survival after renal transplantation. The aim of this study is to evaluate the usefulness of serum N-glycan profiling for prediction of ABMR in patients with LKTx. METHODS From 2004 to 2014, we underwent 250 LKTx in Akita and Hirosaki University Hospital. Of those, we randomly selected 144 cases including 10 recipients with biopsy proven ABMR occurred within 1 month after LKTx, 38 recipients with biopsy proven T cell mediated rejection (TCMR), and 96 patients without any events for serum N-glycan profiling study by using glycoblotting method and MALDI-TOF-MS analysis. All patients were longitudinally followed up for 1 month. To identify the ABMR predictive N-glycan, a total of 36 types of N-glycan levels in each patient were analyzed using logistic regression analysis and ROC curves. RESULTS We found one hybrid typed N-glycans (m/z 2033) concentration at day1 after LKTx was significantly decreased ABMR compare to other groups. The optimal cut-off levels of m/z 2033 was determined to be less than 1.285 μM for the prediction of ABMR based on ROC curves and we calculated a sensitivity of 90.0% and a specificity of 61.4%, with a positive predictive value (PPV) and negative predictive value (NPV) of 14.1% and 98.8%, respectively. To investigate predictive potential for ABMR, Flow-PRA, FCXM-T cell, FCXM B-cell and N-glycan (m/z 2033) were analyzed using logistic regression analysis. The hybrid typed N-glycans m/z 2033 (hazard ratio, 13.8) showed higher hazard ratio than Flow-PRA+ (hazard ratio, 5.76), FCXM T cell+ (hazard ratio, 0.12), FCXM B cell+ (hazard ratio, 0.15), and DSA positive (hazard ratio, 13.2) suggesting strong predictive marker than DSA. CONCLUSIONS These results suggest that the decreasing hybrid typed N-glycan (m/z 2033) may have a potential to predict ABMR in patients undergoing LKTx. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e385 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Daisuke Noro More articles by this author Tohru Yoneyama More articles by this author Yuki Tobisawa More articles by this author Shingo Hatakeyama More articles by this author Mitsuru Saito More articles by this author Yasuhiro Hashimoto More articles by this author Takuya Koie More articles by this author Shigeru Sato More articles by this author Chikara Ohyama More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...